Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease

Increased mTOR activation in idiopathic multicentric Castleman disease

(2020) Daniel J. Arenas et al.   BLOOD

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry

(2019) Fan Zhang et al.   NATURE IMMUNOLOGY

Comprehensive Integration of Single-Cell Data

(2019) Tim Stuart et al.   CELL

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

(2019) David C. Fajgenbaum et al.   JOURNAL OF CLINICAL INVESTIGATION

Integrating single-cell transcriptomic data across different conditions, technologies, and species

(2018) Andrew Butler et al.   NATURE BIOTECHNOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?

(2018) Przemyslaw J. Kotyla   Biomed Research International

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

(2018) Frits van Rhee et al.   BLOOD

Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome

(2017) Noriko Iwaki et al.   Scientific Reports

Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease

(2016) Noriko Iwaki et al.   AMERICAN JOURNAL OF HEMATOLOGY

Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version

(2016) Yasufumi Masaki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Human CD56brightNK Cells: An Update

(2016) Tatiana Michel et al.   JOURNAL OF IMMUNOLOGY

Plasma cells as an innovative target in autoimmune disease with renal manifestations

(2016) Falk Hiepe et al.   Nature Reviews Nephrology

Idiopathic multicentric Castleman's disease: a systematic literature review

(2016) Amy Y Liu et al.   Lancet Haematology

Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes

(2015) Mark Livingstone et al.   PLoS One

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Type I Interferon in the Pathogenesis of Lupus

(2014) M. K. Crow   JOURNAL OF IMMUNOLOGY

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

(2014) Nikhil Munshi et al.   LEUKEMIA & LYMPHOMA

Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases

(2013) Massimo Gadina   JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS

The clinical spectrum of Castleman's disease

(2012) Angela Dispenzieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection

(2012) M. A. Paley et al.   SCIENCE

Genetic susceptibility to systemic lupus erythematosus in the genomic era

(2010) Yun Deng et al.   Nature Reviews Rheumatology

Type I Interferon Modulates Monocyte Recruitment and Maturation in Chronic Inflammation

(2009) Pui Y. Lee et al.   AMERICAN JOURNAL OF PATHOLOGY

Association of IRF5 polymorphisms with activation of the interferon   pathway

(2009) O. J. Rullo et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients

(2008) Timothy B. Niewold et al.   ARTHRITIS AND RHEUMATISM